Related Experiment Video
Updated: Jan 23, 2026

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
Published on: September 6, 2024
Protein tyrosine phosphatase 1B (PTP1B) inhibitors as potential anti-diabetes agents: updated patent review
Rafia Ashfaq1, Hidayat Hussain2
1Department of Chemistry, University of Okara, Okara, Pakistan.
Introduction:
Inhibition of protein tyrosine phosphatase 1B (PTP1B) is a key strategy for improving insulin sensitivity in various cells. This strategy is supported by human genetic data. PTP1B inhibitors are considered an attractive target for the treatment of T2DM because they improve insulin receptor sensitivity and have the ability to reverse insulin resistance-related diseases.
Areas Covered:
This review provides an overview of the patents that were published between January 2019 and December 2023. The efficacy of potent PTP1B inhibitors for the treatment of T2DM is described in this review. The latest patented studies of PTP1B inhibitors (are summarized by using the keywords 'PTP1B inhibitors,' in PubMed, SciFinder, and Google Patents.
Expert Opinion:
There has been tremendous progress in PTP1B drug discovery. Progress has been made with natural products, semi-synthetic natural product derivatives and heterocyclic hybrid compounds. A number of protocols are being pursued in order to enhance the biological effects of PTP1B inhibitors. In addition, these new advances suggest that it may be possible to obtain small-molecule inhibitors of PTP1B with the required potency and selectivity. In addition, future efforts using an integrated medicinal chemistry and structural biology strategy are expected to lead to potent and selective PTP1B inhibitors.
Related Concept Videos
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
SI Units: 2019 Redefinition
A standard set of units has been defined...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Receptor Tyrosine Kinases

